PTC Therapeutics Expands Rare Disease Portfolio with 'Unique Opportunity'

Funkled and Focus Partner to Turn Financial Education into Advice-Ready Clients

Financial education platform Funkled has partnered with advice technology provider Focus to integrate digital client engagement tools directly into its free learning platform. Starting August 1st, Funkled will launch a 30-day content programme with daily modules and podcasts covering financial topics, aiming to address the UK's advice gap where only 8.7% of adults take financial advice.

What This Invesco Insider Move Signals With the Stock Up 63%

Invesco senior managing director Jeffrey H. Kupor sold 26,002 shares valued at $702,314 on July 2, 2026, but this was a non-discretionary tax withholding event related to restricted stock unit vesting, not a voluntary sale. The transaction is insignificant for investors to monitor. More importantly, Invesco posted its 11th consecutive quarter of positive organic growth with $22 billion in net inflows, $2.2 trillion in assets under management, and raised its dividend while authorizing a $1 billion buyback.

Healthcare: Pockets of Alpha

The healthcare sector, down 3.8% year-to-date and the worst performer among S&P 500 sectors, presents selective opportunities despite weak aggregate earnings growth. While the sector faces headwinds with the lowest forward profit margins and weakest 2026 EPS growth outlook, specific subsectors show promise: Pharmaceuticals are rerating as GLP-1 economics mature, Biotech benefits from M&A activity, and smaller-cap healthcare companies outperform large-cap peers. The recommendation is a market-weight position focusing on areas with improving earnings, margins, and catalysts rather than broad sector exposure.

PTC Therapeutics To Present New Sephience Data At The 2026 Society For The Study Of Inborn Errors Of Metabolism Annual Symposium, August 25-28

Barclays Maintains Overweight on PTC Therapeutics, Raises Price Target to $122

Wells Fargo Maintains Overweight on PTC Therapeutics, Raises Price Target to $109

Wells Fargo analyst Benjamin Burnett maintains PTC Therapeutics (NASDAQ:PTCT) with a Overweight and raises the price target from $106 to $109.